Acquisition Opportunity ALG was acquired by Element Materials Technology in 2021, indicating integration into a larger global testing network. This presents cross-sell potential to Element’s clients who may need expanded contract lab capabilities or complementary services in antimicrobial, pharmaceutical, medical device, biotech, and healthcare spaces.

Regulatory Readiness With GLP/GMP compliance, FDA registration, DEA licensing, and ISO/IEC 17025:2017 and A2LA accreditation, ALG can target highly regulated markets and customers seeking validated, quality-driven testing partners, including pharmaceutical brands, medical device manufacturers, and biotech firms.

Geographic Reach Facilities in San Francisco, Minneapolis, and Boston position ALG to serve West Coast, Midwest, and Northeast markets, enabling regional account targeting and collaboration with Element’s larger global footprint to win multi-site contracts.

Infection Prevention Focus ALG emphasizes Helping Protect Life through infection prevention testing across antimicrobial, healthcare, and environmental sectors. This focus aligns with rising demand for rapid, at-risk-health surveillance, offering opportunities in hospitals, clinics, and public health initiatives.

Public-Private Partnerships Historically partnering with EPA, RXinsider, and industry stakeholders signals openness to collaborative programs and case studies. This can be leveraged to initiate joint ventures, RFP responses, and funded research opportunities with government and industry groups.